Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience. [electronic resource]
Producer: 20080311Description: 11-25 p. digitalISSN:- 1528-4336
- Adult
- Aged
- Alkynes
- Anti-HIV Agents -- therapeutic use
- Benzoxazines -- therapeutic use
- CD4 Lymphocyte Count
- Cyclopropanes
- Dideoxynucleosides -- therapeutic use
- Double-Blind Method
- Drug Resistance, Viral
- Drug Therapy, Combination
- Female
- HIV Infections -- drug therapy
- HIV Protease Inhibitors -- therapeutic use
- HIV-1 -- drug effects
- Humans
- Indinavir -- therapeutic use
- Male
- Middle Aged
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.